FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls
A pair of Chinese manufacturers with active pharmaceutical ingredients that were previously shipped to the U.S. have landed in the FDA’s crosshairs thanks to quality shortfalls, poor testing standards ...
Saharsh Davuluri, Neuland Labs, urges API and peptide automation by 2026 to match modern biologics standards.
Forbes contributors publish independent expert analyses and insights. Co-Founder of Fictiv. Stanford MechE. Ford Alum. Forbes 30 Under 30. Despite concerns about rising tariffs and mounting trade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback